FDA View On Amarin Disclosures Undercuts 'Same Labeling' For Biosimilars – AbbVie
This article was originally published in The Pink Sheet Daily
Decision to require labeling for Zarxio that is identical to its reference product cannot be squared with agency's representation in the Vascepa off-label promotion lawsuit that failure to expressly disclose when studies were conducted using other products is misleading, petition says.
You may also be interested in...
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
Pink Sheet reporter and editors discuss whether emotion could be removed from US FDA advisory committees, adverse events and advancing science in gene therapy development, and Capitol Hill’s interest in the ongoing user fee negotiations.
Recent adverse events are ‘speed bumps’ that need to be worked around, biologics center head Peter Marks says; Morgan Stanley’s Peter Hwang asserts high-profile safety issues have added to unpredictability of gene therapy development, dampening investor enthusiasm for the field.